Analysts’ Top Healthcare Picks: ATEC, CAPR

By Austin Angelo

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Alphatec Holdings (NASDAQ: ATEC), Capricor Therapeutics (NASDAQ: CAPR) and DENTSPLY SIRONA Inc (NASDAQ: XRAY) with bullish sentiments.

Alphatec Holdings (NASDAQ: ATEC)

Alphatec Holdings (NASDAQ: ATEC) received a Buy rating and a $4 price target from H.C. Wainwright analyst Swayampakula Ramakanth today. The company’s shares closed on Friday at $1.68, close to its 52-week high of $9.65.

According to TipRanks.com, Ramakanth is ranked 0 out of 5 stars with an average return of -11.5% and a 27.5% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as X T L Biopharmaceuticals Ltd (ADR), Strata Skin Sciences Inc, and Spectrum Pharmaceuticals.

Alphatec Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $4.

Capricor Therapeutics (NASDAQ: CAPR)

In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Capricor Therapeutics (NASDAQ: CAPR), with a price target of $2.15. The company’s shares closed on Friday at $1.05, close to its 52-week high of $4.09.

According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of -20.5% and a 28.3% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Applied Genetic Technologies, and ImmunoCellular Therapeutics.

Capricor Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $2.15.

DENTSPLY SIRONA Inc (NASDAQ: XRAY)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on DENTSPLY SIRONA Inc (NASDAQ: XRAY) today. The company’s shares closed on Friday at $55.33, close to its 52-week high of $65.68.

According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -12.5% and a 27.9% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as RegeneRx Biopharmaceuticals Inc, Biospecifics Technologies Corp, and Synergy Pharmaceuticals Inc.

Currently, the analyst consensus on DENTSPLY SIRONA Inc is Moderate Buy and the average price target is $70, representing a 26.5% upside.

In a report issued on August 9, Stifel Nicolaus also reiterated a Buy rating on the stock with a $66 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.